Synthego adds new member to advisory board.
M2 PHARMA-September 22, 2017-Synthego adds new member to advisory board
(C)2017 M2 COMMUNICATIONS
Synthego, a US-based Genome engineering solutions provider, has added Sir Andrew Witty to its advisory board, it is reported today.
In the new role, Witty will work on biological research and grow the company's application development and bioinformatics expertise.
Witty has previously served on the board of directors at GlaxoSmithKline, where he was chief executive officer from 2008 - 2017. He has more than 30 years' experience and his biopharma expertise ranges from product management and business development, to strategic partnerships.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Sep 22, 2017|
|Previous Article:||Alligator Bioscience announces presentation of ADC-1013 intratumoural clinical phase I study results at SITC in November 2017.|
|Next Article:||Shady Grove Fertility Simplifies Egg Donation, Donor Selection with New Portal.|